Netris Pharma reported positive Phase Ib data for its first-in-class netrin-1 inhibitor NP-137 in pancreatic ductal adenocarcinoma, showing activity against chemotherapy resistance. The company’s update frames NP-137 as a potential add-on strategy for a disease where resistance mechanisms limit durable benefit. The results are being positioned as an early clinical signal that netrin-1 blockade may meaningfully improve chemotherapy response rates or depth of response. Pancreatic cancer remains one of the highest unmet-need areas in oncology, with limited options once resistance emerges. While the data are preliminary, the readout keeps attention on the tumor-microenvironment signaling axis as a tractable drug target in pancreatic cancer.